Published in J Viral Hepat on March 06, 2015
Bone health in HIV and hepatitis B or C infections. Ther Adv Musculoskelet Dis (2016) 0.75
Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med (1998) 32.43
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA (2004) 10.40
Matching methods for causal inference: A review and a look forward. Stat Sci (2010) 9.78
Incidence and mortality of hip fractures in the United States. JAMA (2009) 6.05
Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS (2006) 5.58
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA (2014) 4.49
Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med (2002) 4.38
Identification of fractures from computerized Medicare files. J Clin Epidemiol (1992) 3.26
Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care (2005) 3.19
Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey. Ann Intern Med (2011) 2.94
Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis (2010) 2.20
Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis (2003) 2.20
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18
Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One (2011) 2.11
Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem (2001) 1.99
The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients. HIV Clin Trials (2007) 1.97
Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS (2012) 1.90
AGA technical review on osteoporosis in hepatic disorders. Gastroenterology (2003) 1.89
Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis (2011) 1.83
Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis (2003) 1.80
Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab (2006) 1.72
Racial differences in fracture risk. Epidemiology (1994) 1.54
Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis (2004) 1.54
A methodology for building an AIDS research file using Medicaid claims and administrative data bases. J Acquir Immune Defic Syndr (1991) 1.44
Recent trends in hip fracture rates by race/ethnicity among older US adults. J Bone Miner Res (2012) 1.44
Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS (2008) 1.40
Descriptive analyses of the integrity of a US Medicaid claims database. Pharmacoepidemiol Drug Saf (2003) 1.38
Hepatic osteodystrophy. Hepatology (2001) 1.37
Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol (2005) 1.37
HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol (2008) 1.35
Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection. Hepatology (2012) 1.16
Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol Metab (2004) 1.09
Variations in hip fracture hospitalization rates among different race/ethnicity groups in New York City. Ethn Dis (2004) 1.08
Review of hepatitis B therapeutics. Clin Infect Dis (2010) 1.06
Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr (2013) 1.05
Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men. AIDS (2009) 1.04
High prevalence of reduced bone mineral density in primary HIV-1-infected men. AIDS (2010) 1.02
Bone disease in cholestatic liver disease. Gastroenterology (1995) 0.98
Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy. Clin Endocrinol (Oxf) (2006) 0.95
Prevalence of diagnosed chronic hepatitis B infection among U.S. Medicaid enrollees, 2000-2007. Ann Epidemiol (2014) 0.91
Oestradiol and testosterone blood levels in patients with viral cirrhosis and hepatocellular carcinoma. Eur J Gastroenterol Hepatol (1997) 0.90
Risk factors for bone loss in chronic active hepatitis and primary biliary cirrhosis. Scand J Gastroenterol (1994) 0.88
Prevalence of low bone mineral density in men and women infected with human immunodeficiency virus 1 and a proposal for screening strategy. J Clin Densitom (2012) 0.86
Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection. J Hepatol (2014) 0.85
Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? J Infect Dis (2014) 0.83
Chronic viral hepatitis is associated with low bone mineral density in HIV-infected patients, ANRS CO 3 Aquitaine Cohort. J Acquir Immune Defic Syndr (2013) 0.80